CALGARY, Alberta -- Liberty Analytics Co., a leading provider of large, small- and micro-cap independent investment research, today initiated coverage on Home Diagnostics, Inc. . Liberty Analytics is currently offering a complimentary trial subscription.
Last week was very active with new mergers and acquisitions announced, rumors of deals for some very well know names like Harley-Davidson (HOG) and Polycom (PLCM), and the successful completion of two acquisitions.
Polycom, widely recognized for its Klingon starship shaped conference phones, had an interesting ride last week with the stock jumping more than 10% from Tuesday’s close of $30.44 to an intraday high of $34.14 on Wednesday on nearly 10...
We are introducing a new service called Merger Arbitrage Mondays to highlight merger arbitrage opportunities that exist in acquisitions that are yet to be completed. If you are not familiar with merger or risk arbitrage, you can read about it in a section of the March 2009 investment newsletter titled Merger Arbitrage and the Pfizer-Wyeth Deal (PFE). That deal delivered gains of 27.34% including dividends over a 7.5 month period. On an annualized ...
The Russell 3,000 is down about 2.5% year to date, and the average stock in the index is down 1.81%. While the index is only down slightly, just 35% of stocks in the index are up year to date. Even though the ratio of down stocks to up stocks is about 2 to 1, 76 stocks in the index are up more than 25% year to date while 58 are down more than 25%.
Below we highlight the best and worst performing stocks in the...
It’s official, the new list of Russell 3000® stocks has been unveiled and a big lineup of healthcare sector companies who were looking to bring value to their shareholders and expose their stocks to a broader base of institutional investors have succeeded.
Certainly, speaking to the growth of the sector was the fact that nearly six times more stocks were added to the list from the BioMed/Healthcare segment of the market than were deleted.
Shares of Home Diagnostics (HDIX) have surged by nearly 50% since I profiled the company in mid-December as a turnaround value play from the ETF Innovators Healthcare Cost Containment Index. A search for compelling values among these companies today led me to generic drug maker Hi-Tech Pharmacal (HITK).
Shares of HITK are down by about 10% in the past five days on light volume and no news headlines,...
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together.
Stock News 
Hickey and Walters (
